Phase I trial of post transplant immunization with autologous myeloma idiotype-KLH [keyhole limpet hemocyanin]/GM-CSF [granulocyte macrophage colony-stimulating factors] in myeloma patients following autologous or allogeneic marrow or stem cell transplantation.

Trial Profile

Phase I trial of post transplant immunization with autologous myeloma idiotype-KLH [keyhole limpet hemocyanin]/GM-CSF [granulocyte macrophage colony-stimulating factors] in myeloma patients following autologous or allogeneic marrow or stem cell transplantation.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 May 2017

At a glance

  • Drugs Melanoma vaccine (Primary) ; Sargramostim (Primary) ; Aldesleukin
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 Mar 2012 Planned end date added as 1 Dec 2002 as reported by ClinicalTrials.gov record.
    • 26 Mar 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 20 May 2010 Actual end date (Aug 2006) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top